drugset / Trial / NCT07102316
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
RandomizedCrossoverOpen-labelTreatment
Summary
The primary objective of this study is to determine the relative bioavailability of treprostinil (TRE) between the TPIP F2 and TPIP F3 at 3 capsule strengths, dose A, dose B, and dose C, in healthy participants following a single inhalation of TPIP dose.
Timeline
- Start
- 2025-08-19
- Primary completion
- 2025-10-25
- Completion
- 2025-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPIP F2 | Unknown | — | Inhaled |
| Subject | TPIP F3 | Unknown | — | Inhaled |
Indications
No indication recorded.